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Objective: Successful mitral valve replacement in young children is limited by the
lack of small prosthetic valves. Supra-annular prosthesis implantation can facilitate
mitral valve replacement with a larger prosthesis in children with a small annulus,
but little is known about its effect on the outcomes of mitral valve replacement in
young children.
Methods: One hundred eighteen children underwent mitral valve replacement at 5
years of age or younger from 1976–2006. Mitral valve replacement was supra-an-
nular in 37 (32%) patients.
Results: Survival was 74% 6 4% at 1 year and 56% 6 5% at 10 years but improved
over time (10-year survival of 83% 6 7% from 1994–2006). Factors associated with
worse survival included earlier mitral valve replacement date, age less than 1 year,
complete atrioventricular canal, and additional procedures at mitral valve replace-
ment, but not supra-annular mitral valve replacement. As survival improved during
our more recent experience, the risks of supra-annular mitral valve replacement
became apparent; survival was worse among patients with a supra-annular prosthesis
after 1991. A pacemaker was placed in 18 (15%) patients within 1 month of mitral
valve replacement and was less likely in patients who had undergone supra-annular
mitral valve replacement. Among early survivors, freedom from redo mitral valve re-
placement was 72%6 5% at 5 years and 45%6 7% at 10 years. Twenty-one patients
with a supra-annular prosthesis underwent redo mitral valve replacement. The second
prosthesis was annular in 15 of these patients and upsized in all but 1, but 5 required
pacemaker placement for heart block.
Conclusions: Supra-annular mitral valve replacement was associated with worse sur-
vival than annular mitral valve replacement in our recent experience. Patients with su-
pra-annular mitral valve replacement were less likely to have operative complete heart
block but remained at risk when the prosthesis was subsequently replaced.
M
itral valve replacement (MVR) in infants and young children is an uncom-
mon operation that historically has carried a higher mortality and worse
long-term outcome than MVR in older children.1-13 One of the limiting
factors in successful MVR in young children has been the lack of appropriately sized
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LA 5 left atrium
MR 5 mitral regurgitation
MS 5 mitral stenosis
MV 5 mitral valve
MVR 5 mitral valve replacement
PA 5 pulmonary artery
prosthetic valves. In certain circumstances, a mitral valve
(MV) prosthesis is implanted in a supra-annular position
(ie, in the left atrium [LA] above the MV annulus). Although
this technique allows for a larger prosthesis to be placed, it
can compromise LA volume and compliance and conse-
quently contribute to LA hypertension in the absence of
prosthetic valve obstruction.14 There are few studies with
long-term follow-up after MVR in young children, and
almost no published information on early or late results of
supra-annular MVR.3,14,15 In particular, despite the well-
characterized hemodynamic abnormalities that can result
from supra-annular MVR,14 little is known about either early
or late outcome after supra-annular MVR or about the poten-
tial for subsequent replacement of the prosthesis in an annular
implant position.
Materials and Methods
This study was approved by the Children’s Hospital Boston Com-
mittee on Clinical Investigation.
Patients
Patients who underwent MVR at Children’s Hospital Boston be-
tween 1976–2006 were ascertained from the database of the cardio-
vascular program. Patients were excluded if age at MVR was greater
than 5 years (60 months), if a prior MVR had been performed else-
where, or if the MV did not support the systemic ventricle in a biven-
tricular circulation at the time of MVR.
MVR
Indications for MVR, decisions regarding repair versus replace-
ment, and prosthesis type varied over time according to clinical
judgment and current practice and technology. Prosthesis type,
size, and implant position were at the discretion of the surgeon. Anti-
coagulation therapy also varied over time, and was generally in
keeping with prevailing practice.
Data Analysis
The primary outcome was survival over time after MVR. Secondary
outcomes included early post-MVR survival (for at least 30 days and
discharge from the hospital), freedom from redo MVR, freedom
from placement of a permanent pacemaker, and freedom from other
prosthesis-related complications. Analysis of freedom from perma-
nent pacemaker placement only included patients who survived at
least 2 weeks after MVR (ie, need for permanent pacing might
have been indeterminate in patients who died within 2 weeks ofThe Journal of ThorMVR) and did not have a pacemaker before MVR (ie, not at risk).
Independent variables analyzed for association with outcomes in-
cluded date of MVR (divided into 5-year periods, decades, and 3 pe-
riods optimized to discrimination of survival over time: 1976–1982,
1983–1993, and 1994–2006), age, weight, weight percentile for age,
underlying cardiac diagnosis, indication for MVR (mitral stenosis
[MS], mitral regurgitation [MR], or MS and MR), associated anom-
alies, prior and concurrent interventions, use of a supra-annular ver-
sus annular prosthesis, prosthesis size, and the ratio of prosthesis
diameter to patient weight. Time-dependent outcomes were as-
sessed with Kaplan–Meier analysis and multivariable Cox regres-
sion analysis. For comparison of continuous or categorical
variables between groups, independent-samples t tests and c2 anal-
ysis were used, respectively. For comparison of preoperative and
postoperative data within patients, paired t test analysis was used.
Multivariable analysis of discrete outcomes was performed by using
multiple logistic regression. Data are presented as means6 standard
deviation or medians (range).
Results
Patients
From 1976–2006 inclusive, 118 children underwent MVR at
5 years of age or younger. The median age was 16.3 months
(range, 3 days–60 months), with 50 (42%) patients 1 year of
age or younger and 84 (71%) patients 2 years of age or youn-
ger. Approximately half as many patients underwent MVR
between 1996 and 2006 (n 5 25) as during each of the prior
decades (1976–1985, n 5 48; 1986–1095, n 5 45). In con-
trast, the number of patients 5 years of age or younger who
underwent MV repair and balloon dilation of the MV in-
creased substantially during this period (Figure 1). There
Figure 1. During the time period covered by this study, the number
of mitral valve replacement (MVR) procedures (white bars) has
decreased, whereas the numbers of surgical mitral valve (MV) re-
pair (diagonally hatched bars) and balloon MV dilation (stippled
bars) procedures have increased. Among patients undergoing
MVR, those in whom a prior MV repair had been performed, not in-
cluding initial repair of atrioventricular (AV) canal (whether com-
plete, partial, or transitional), are shown in black. The number of
patients undergoing surgical MV repair does not include patients
having initial repair of AV canal.acic and Cardiovascular Surgery c Volume 136, Number 4 955
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Dwas no difference in age at MVR between decades. The me-
dian weight at the time of MVR was 7.5 kg and ranged from
3.0 to 18.0 kg. Weight for age at the time of MVR was less
than the first percentile in 65 (55%) patients and less than
the third percentile in 87 (74%) patients.
Underlying MV-related diagnoses are summarized in
Table 1. The indication for MVR was MR in 72 (61%) pa-
tients, MS in 20 (17%) patients, and a combination of MR
and MS in 26 (22%) patients. There was a shift in indications
for MVR over time, such that patients were less likely to un-
dergo MVR for MS and more likely to undergo MVR for
mixed MR and MS during the latter part of our experience
(Figure E1). This trend is probably due to an increased num-
ber of patients undergoing balloon or surgical mitral valvulo-
plasty for MS who developed MR, patients who had
secondary MS after undergoing surgical mitral valvuloplasty
for MR, or both. There was no difference in age at MVR ac-
cording to hemodynamic indication. Mean pulmonary artery
(PA) pressure measured at catheterization before MVR (n5
80) was 46.66 19.2 mm Hg, mean LA pressure was 20.76
7.2 mm Hg, and indexed pulmonary vascular resistance
index was 7.8 6 6.0 mm Hg $ L21 $ min21 $ m22.
Cardiovascular interventions were performed before
MVR in 98 (83%) patients (Table 2). Prior interventions
for MS or MR, not including initial repair of an atrioventric-
ular (AV) canal (any type, including partial), were performed
in 42 (36%) patients. Prior MV procedures were performed
a median of 3.0 months before MVR (range, 2 days–33
months). Among 44 patients who previously underwent re-
pair of an AV canal, MVR was performed a median of 1.6
months (range, 1 day–42 months) after the original repair.
MVR
MV repair was attempted at the same operation as MVR in 12
(10%) patients before the decision was made to replace the
valve. Additional procedures were performed in 39 patients
(Table 2).
TABLE 1. Primary diagnosis involving the MV in 118
patients undergoing MVR at 5 years of age or younger
Congenital MS 37 (31%)
Congenital MR 15 (13%)
Complete or transitional AV canal 42 (36%)
With tetralogy of Fallot 6 (5%)
Partial AV canal (primum atrial septal defect, cleft MV) 10 (8%)
Isolated cleft MV 4 (3%)
Endocarditis 3 (3%)
Marfan syndrome 2 (2%)
Tetralogy of Fallot with associated abnormal MV 2 (2%)
MV prolapse with MR (chronic anemia) 1 (1%)
Anomalous left coronary artery from the PA 1 (1%)
Traumatic MR (Konno procedure) 1 (1%)
MV, Mitral valve; MVR, mitral valve replacement; MS, mitral stenosis; MR,
mitral regurgitation; AV, atrioventricular; PA, pulmonary artery.956 The Journal of Thoracic and Cardiovascular Surgery c OcThe types and sizes of MV prostheses are summarized in
Table E1. Small-diameter dura mater valves were used in
the earliest years of our experience, and the current prefer-
ence is to implant low-profile St Jude HP prostheses. The
prosthesis was placed in the supra-annular position in 37
(32%) patients. By means of univariable analysis, supra-an-
nular prosthesis placement was associated with age younger
than 2 years at MVR (odds ratio [OR], 7.0; 95% CI, 2.0–24;
P 5 .001), lower weight (6.6 6 2.0 vs 8.6 6 3.5 kg, P 5
.002), an underlying diagnosis of congenital MS (OR, 16.8;
95% CI, 6.4–44.1; P , .001), and MS (with or without as-
sociated MR) as an indication for MVR (OR, 10.9; 95% CI,
4.3–27.2; P , .001). By means of multivariable logistic
regression, lower weight and congenital MS were indepen-
dently associated with increased likelihood of supra-annular
MVR. The median prosthesis size was smaller in patients
receiving a supra-annular MVR than in those in whom
the prosthesis was annular (17 vs 19 mm, P 5 .005), but
there was no difference when the analysis was limited to
patients younger than 2 years of age, which included all
but 3 of the patients with a supra-annular implant. As de-
picted in Figure 2, supra-annular MVR was performed in
49% of cases between 1986–1995, which was significantly
more often than in earlier or later years, when it was
TABLE 2. Prior and simultaneous cardiovascular
interventions
Prior interventions
Any intervention 98 (83%)
Surgical intervention 83 (70%)
Catheter intervention 30 (25%)
MV procedure 42 (36%)
MV surgery (not including initial AV canal repair) 26 (22%)
MV balloon valvuloplasty 18 (15%)
Supravalvar mitral ring resection 6 (5%)
Surgical or transcatheter intervention
for aortic coarctation
22 (19%)
Surgical or transcatheter intervention
for aortic stenosis
12 (8%)
Intervention for subaortic stenosis 7 (6%)
Repair of complete AV canal 35 (30%)
Repair of partial AV canal 9 (8%)
Ventricular septal defect closure 10 (8%)
Tetralogy of Fallot repair 8 (7%)
Other 9 (7%)
Additional interventions at the time of MVR
Any simultaneous intervention 39 (33%)
Aortic valve repair or replacement 8 (7%)
Intervention for subaortic stenosis 12 (10%)
Repair of complete AV canal 7 (6%)
Ventricular septal defect closure 8 (7%)
Left atrial augmentation 2 (2%)
Tricuspid valve repair 2 (2%)
Other 7 (6%)
MV, Mitral valve; AV, atrioventricular; MVR, mitral valve replacement.tober 2008
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Dperformed in 21% of cases (OR, 3.7; 95% CI, 1.7–8.4;
P 5 .001).
A number of methods of indexing prosthesis size to pa-
tient size were calculated; ultimately, the ratio of prosthesis
size (diameter of the sewing ring) to patient weight was found
to be most useful. The median prosthesis size/weight ratio
was 2.4 (95% CI, 1.2–5.7), with an almost linear inverse
relationship between age and size/weight ratio. Among pa-
tients 1 year of age or younger at MVR, all had a prosthesis
size/weight ratio of greater than 2, and with only a few excep-
tions, patients older than 1 year of age had a prosthesis size/
weight ratio of less than 3.
Outcomes
Survival. Follow-up data were available for all but 6
patients, who were referred from elsewhere and discharged
from the hospital alive but had no subsequent data available.
Early mortality (30 days or before hospital discharge) was
19% (n5 23) and decreased significantly from decade to de-
cade (Figure 2). Factors associated with increased risk of
early mortality included surgical intervention during the
earliest portion of our experience (1976–1982: 13/32 [41%]
compared with 1983–1993: 8/49 [16%] or 1994–2006:
2/37 [5%]; P, .001), age less than 1 year at MVR (OR, 2.5;
95% CI, 1.0–6.5; P 5 .045), and other procedures at the
time of MVR (OR, 3.4; 95% CI, 1.3–8.8; P5 .008). Among
50 patients 1 year of age or younger at MVR, all 14 early
deaths occurred in patients with a prosthesis size/weight ratio
greater than 3 (P 5 .02). Overall, supra-annular MVR was
not associated with early mortality. However, supra-annular
Figure 2. Bar graph depicting the number of mitral valve replace-
ment (MVR) procedures broken down by early survivors (white
bars) and early deaths (hatched bars) in 5-year blocks (the most
recent block, 2001–2006, is 6 years). Patients in whom a supra-an-
nularMVRwas performed are depictedwith black bars, which are
accurately aligned across bars for early survivors and early
deaths.The Journal of ThoMVR was strongly associated with increased risk of early
death during the most recent half of our experience (24%
early mortality since 1991 compared with 5% among patients
receiving an annular MVR), with 5 of 6 early deaths during
this period in patients with a supra-annular implant. In con-
trast, none of the 14 early deaths during the first decade
were in patients with a supra-annular implant.
Twenty-three patients died during follow-up: 4 after redo
MVR, 2 after heart or heart-lung transplantation, 4 from
arrhythmia or ventricular failure, 3 with infection, 2 with
documented dysfunction or thrombosis of the MV prosthesis,
1 from right ventricular failure after surgical intervention for
pulmonary valve replacement, and 7 from unknown causes.
Among current survivors, 35 have been followed for 10 years
or longer after MVR, 11 for 20 years or longer (6 with an ini-
tial supra-annular MVR), and 6 for 25 years or longer (4 with
a supra-annular MVR).
Overall, time-related survival estimated by means of
Kaplan–Meier analysis was 74%6 4% at 1 year, 62%6 5%
at 5 years, 56% 6 5% at 10 and 15 years, and 53% 6 6% at
20 years. Survival, as determined by means of Kaplan–Meier
analysis, also improved significantly over our experience,
from 56% 6 9% at 1 year and 46% 6 9% at 5 and 10 years
during the first period (1976–1982) to 92% 6 5% at 1 year
and 83% 6 7% at 5 and 10 years during the third period
(1994–2006, Figure 3). Compared with patients treated
from 1976–1982, survival among patients treated between
1983–1993 was better through 5 to 7 years, but the difference
was eclipsed by 10 years. There was a significant improve-
ment in intermediate survival after 1994.
Factors associated with shorter survival over time by
means of univariable and multivariable Cox regression in-
cluded MVR at an earlier date (relative to 1994–2006:
1976–1982, B 5 1.53, P 5 .01, multivariable P 5 .017;
1983–1993, B 5 1.27, P 5 .003, multivariable P 5 .017),
Figure 3. Kaplan–Meier survival curves for patients undergoing
mitral valve repair between 1976–1982, 1983–1993, and 1994–2006.
Dashed lines represent 95% confidence intervals.racic and Cardiovascular Surgery c Volume 136, Number 4 957
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Dage less than 1 year at MVR (B520.60, P5 .04, multivari-
able P 5 .016), a diagnosis of complete AV canal (B 5
20.78, P 5 .009, multivariable P 5 .001), and other proce-
dures at the time of MVR (B 5 20.89, P 5 .001, multivari-
able P 5 .001). Notably, supra-annular MVR was not
associated with time-related survival overall (P 5 .53) but,
as was the case with early mortality, was associated with
worse survival over time during the most recent half of our
experience. Among patients in this series undergoing MVR
since 1991, 1- and 5-year survivals were 96% and 90%, re-
spectively, among those with annular MVR, and 67% and
52%, respectively, among patients with a supra-annular
implant (P 5 .004).
Survival over time was assessed for patients who survived
the early post-MVR period to differentiate factors associated
with perioperative and later mortality. Among early survi-
vors, placement of a permanent pacemaker in the peri-MVR
period (B 5 21.4, P 5 .001), a diagnosis of complete AV
canal (B 5 21.01, P 5 .01), and smaller MVR prosthesis
size (B 5 20.23, P 5 .03) were associated with worse sur-
vival over time. By means of multivariable Cox regression,
peri-MVR pacemaker placement (P5 .003) and smaller pros-
thesis size (P5 .04) were associated with worse survival. Dur-
ing the latter half of our experience, time-related survival
among early survivors was worse among those with a supra-
annular MVR (68% at 5 years) than those with an annular im-
plant (94% at 5 years,P5 .05). Of 8 late deaths in patients with
a supra-annular MVR, 2 occurred early after redo MVR, 2
early after heart or heart-lung transplantation, 1 from prosthe-
sis thrombosis, 1 from ventricular failure, 1 from infection,
and 1 from unknown causes. All 4 of the patients who died
after reoperation had pulmonary hypertension, with a pulmo-
nary vascular resistance index ranging from 6.4 to 19 mm
Hg $ L21 $ min21 $ m22 on preoperative catheterization.
Pacemaker placement. At the time of MVR, 6 patients
had already had a permanent pacemaker. Another 18 patients
had a pacemaker placed within 1 month of MVR for complete
AV block (n5 16) or sinus node dysfunction (n5 2). An ad-
ditional 10 patients had a pacemaker placed during follow-up
for complete or high-grade AV block (n 5 8) or sinus node
dysfunction (n5 1), either after redo MVR (n5 8) or closure
of a paravalvar leak (n 5 1), and 1 for resynchronization of
ventricular dysfunction unrelated to MV reintervention.
Among the 99 patients who survived at least 2 weeks after
MVR and did not have a preexisting pacemaker, a diagnosis
of complete AV canal (OR, 5.6; 95% CI, 1.9–16.9; P5 .001)
and MVR during the first half of our experience (OR, 5.3;
95% CI, 1.4–19.6; P 5 .008) were the only independent
risk factors for early post-MVR pacemaker placement by
means of multivariable logistic regression. By using univari-
able analysis, patients with a supra-annular prosthesis had
a lower risk of pacemaker placement in the early post-
MVR period than those with an annular prosthesis (OR,
0.1; 95% CI, 0.01–0.73; P 5 .01); 1 (3%) of 32 patients958 The Journal of Thoracic and Cardiovascular Surgery c Owith a supra-annular prosthesis had a pacemaker placed com-
pared with 17 (16%) of 66 patients with an annular MVR.
Freedom from pacemaker placement among 2-week
survivors was 81% at 1 month and 1 year, 78% at 5 years,
and 69% at 10 years after MVR (Figure 4). By means of
multivariable Cox regression, independent risk factors for
shorter freedom from pacemaker placement over time were
a diagnosis of complete AV canal (B 5 20.85, P 5 .03)
and a prosthesis/weight ratio of less than 3 at the time of
MVR (B 5 21.2, P 5 .03).
Redo MVR and other reinterventions. Forty-four pa-
tients underwent a total of 51 redo MVR procedures during
follow-up. Indications for the first redo MVR were thrombus,
endocarditis, or clear prosthesis dysfunction in 9 patients;
subaortic stenosis requiring surgical intervention in 4 patients
(2 caused by prosthesis impingement); and prosthetic MS, in-
cluding pannus-related obstruction, in 31 patients. Prosthesis
size was increased in essentially all patients (Figure 5). As
noted above, 8 (18%) of these 44 patients had a permanent
pacemaker placed for complete AV block early after redo
MVR.
Among 95 early survivors, freedom from redo MVR was
72% 6 5% at 5 years and 45%6 7% at 10 years (Figure 4).
Factors associated with shorter freedom from redo MVR
among early survivors included younger age (B 5 20.37),
smaller prosthesis size (B520.32, P, .001), and supra-an-
nular prosthesis position (B520.69, P5 .02). By means of
multivariable analysis, smaller prosthesis size was the only in-
dependent predictor of shorter freedom from redo MVR. Early
mortality after the first redo MVR procedure was 9% (4/44).
Of 37 patients who received a supra-annular prosthesis, 21
underwent redo MVR, 6 (29%) cases of which were supra-
annular. In all but 1 of these patients, including all 15 who
had redo MVR in the annular position, the second prosthesis
was able to be upsized (Figure 5). However, among the 15
Figure 4. Kaplan–Meier curves depicting freedom from redo mi-
tral valve replacement (MVR) and placement of a permanent pace-
maker. Dashed lines represent 95% confidence intervals.ctober 2008
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Dpatients who underwent redo MVR in the annular position
after an original supra-annular MVR, 5 had complete AV block
and underwent pacemaker placement after the first redo MVR.
No patient who underwent an initial annular MVR had a redo
prosthesis placed in the supra-annular position.
Six patients underwent 8 procedures to close paravalvar
leaks, 2 in the catheterization laboratory and 6 surgically.
LA augmentation was performed in 4 patients at the time
of reoperation (first redo MVR in 2, second redo MVR in
1, and subaortic stenosis resection without redo MVR in 1),
including 2 who also underwent fibrous body reconstruction
and MV annulus enlargement along with redo MVR and aor-
tic valve replacement. All 4 of these patients initially had a
supra-annular prosthesis.
Three patients underwent heart transplantation for ventric-
ular failure (1 heart-lung transplantation), and 2 died early af-
ter transplantation. Other reinterventions during follow-up
included aortic valve replacement in 5 patients, relief of sub-
aortic stenosis in 10 patients, procedures for recurrent aortic
coarctation in 3 patients, and replacement of a right ventricle–
PA conduit in 2 patients.
Hemodynamic status. Among patients with a supra-annu-
lar MVR initially, 21 underwent catheterization during follow-
up, all before redo MVR or other surgical reintervention. Some
of the characteristic hemodynamic findings in these patients
have been reported previously.14 We also found that of 11 pa-
tients with a supra-annular MVR and increased pulmonary vas-
cular resistance index (6.3–12.8 mm Hg $L21 $min21 $m22),
all 5 who were tested with hyperoxia and inhaled nitric oxide
demonstrated some degree of reactivity, with reductions in
pulmonary vascular resistance index by 25% to 54%, from
a median of 11.5 to 7.6 mm Hg $ L21 $ min21 $ m22. Among
Figure 5. Line graph depicting prosthesis diameter at the time of
the initial mitral valve repair (MVR) and first redo MVR in patients
who initially underwent a supra-annular MVR (filled circles
and lines) and those who underwent standard annular MVR (open
circles and dashed lines).The Journal of Thopatients who underwent redo MVR and had preoperative
catheterization, pulmonary vascular resistance before reopera-
tion was higher in those with a supra-annular prosthesis than in
those without (7.26 3.6 vs 4.16 2.0 mm Hg $ L21 $ min21 $
m22, P5 .02).
An aneurysm of the atrialized portion of the left ventricle
(between the prosthesis and native MV annulus) was observed
in 2 patients (Figure E2), with no obvious consequences.
Discussion
Supra-annular MVR
Although the frequency of MVR in young patients has de-
creased over the past 10 to 15 years of our experience, with
more aggressive approaches to MV repair for MR and MS
and more frequent use of balloon mitral valvuloplasty for
MS, MVR remains the only treatment option for MV dys-
function in some cases. One of the major challenges in the
treatment of MV disease in infants and young children is
the limitation of small prostheses for MVR. One option for
implanting or maximizing the size of a mechanical MV pros-
thesis in small patients is to place the valve in a supra-annular
position, effectively within the LA. Despite the potential ben-
efits of a larger prosthesis in small children, supra-annular
MVR has potential drawbacks, including reduction of LA
volume and compliance14 and aneurysm formation in the
ventricularized segment of LA between the prosthesis and
annulus.15
In our experience, approximately one third of patients who
underwent MVR at 5 years of age or younger received a supra-
annular prosthesis. Supra-annular MVR was more common in
younger and smaller patients, those with congenital MS, and
during the period from 1986–1995. Supra-annular MVR was
associated with improved short-term survival and freedom
from complete AV block compared with standard annular
MVR during the early part of our experience, when survival
overall was quite poor. Perhaps as a result, supra-annular
MVR was used more frequently during the middle portion
of our experience. As short-term survival overall improved
during our more recent experience, the risks associated with
supra-annular MVR became apparent because both early
and intermediate survivals were worse among patients with
a supra-annular prosthesis after 1991. Nevertheless, among
patients who underwent successful supra-annular MVR dur-
ing the earlier years of our experience, there are a number of
long-term survivors who continue to do well, including 4 of
the 6 patients followed for more than 25 years in this series.
Freedom from redo MVR was shorter in patients with a su-
pra-annular prosthesis, but more than 70% of patients who
underwent redo MVR after supra-annular MVR were able
to have a larger prosthesis placed in the annular position.
One of the most notable findings of this study was that the
risk of post-MVR complete AV block requiring permanent
pacemaker placement was lower in children who had a su-
pra-annular prosthesis than in those who received an annularracic and Cardiovascular Surgery c Volume 136, Number 4 959
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Dprosthesis. This finding seems reasonable, given the proxim-
ity of the MV annulus and fibrous body to the penetrating
bundle. Unfortunately, also consistent with this observation,
33% of patients who underwent annular MVR after prior su-
pra-annular MVR had AV block requiring permanent pacing
after the redo MVR.
Although it is encouraging that supra-annular MVR is not
associated with worse survival overall than annular MVR in
infants and young children, survival trends during the most
recent half of our experience better reflect the relative risk
of supra-annular MVR in the current era. Whether the risks
of supra-annular MVR are a function of the procedure per
se or of the underlying anatomic substrate that is not amena-
ble to annular MVR is difficult to know. However, it is likely
that the effects of a supra-annular prosthesis are at least par-
tially responsible. As reported previously, LA compliance is
reduced in patients with a supra-annular MV prosthesis,
which predisposes to a steep and high increase in LA pressure
during ventricular systole (ie, V-wave) and consequent LA
hypertension out of proportion to prosthetic MS.14 These ad-
verse hemodynamic effects might have important clinical im-
plications. LA and pulmonary venous hypertension might
contribute to PA hypertension, which is one of the most seri-
ous potential adverse outcomes in this patient population.
Generally, transprosthesis flow velocity estimated by means
of Doppler echocardiographic analysis is a good indicator of
LA and PA pressure. However, because the prosthetic MS
gradient assessed by Doppler analysis might underrepresent
the severity of LA hypertension in patients with poor LA
compliance, the risk of PA hypertension might not be appre-
ciated in these patients. Accordingly, practitioners should
have a low threshold for catheterization in patients with clin-
ical symptoms that do not appear concordant with echocar-
diographic findings after supra-annular MVR.
The importance of pulmonary hypertension after supra-
annular MVR in young children is difficult to assess from
this study. However, it is noteworthy that all 4 patients
with a supra-annular prosthesis who died after reoperation
had increased pulmonary vascular resistance. Among the
small number of patients found to have increased pulmonary
vascular resistance at catheterization after supra-annular
MVR, 5 were tested with inhaled nitric oxide, and all re-
sponded with a decrease (but not normalization) of the pul-
monary vascular resistance index. Thus, nitric oxide is
likely to be a useful adjunct in the perioperative management
of children with pulmonary hypertension who undergo redo
MVR.
Other Findings
Aside from the findings relating to supra-annular MVR, there
are several notable results of this study. Over the past 3 de-
cades, the approach to MV disease in infants and young chil-
dren has changed substantially, with more aggressive efforts
to treat MS and MR without MVR, including balloon dilation960 The Journal of Thoracic and Cardiovascular Surgery c Ocof the MV for MS and surgical MV repair for MR.16,17 MVR
is performed half as frequently now as it was 20 or 25 years
ago, whereas the volume of surgical MV repair and balloon
MV dilation procedures has grown dramatically. With these
changes in practice, operative and late survivals have also
continued to improve, with 1- and 10-year survivals increas-
ing from 56% 6 9% and 46% 6 9% between 1976–1982 to
92% 6 5% and 83% 6 7% between 1994–2006. Other
factors associated with worse survival, which are similar to
findings of other series4 and include age less than 1 year
at MVR, larger prosthesis size/patient weight ratio, and a
diagnosis of complete AV canal, have not changed over
this long study period. Of note, among early survivors, sur-
vival over time was worse for those who required a permanent
pacemaker in the peri-MVR period.
Limitations
This study is limited by its retrospective design and inclusion
of patients managed over a 30-year period. Also, it is impor-
tant to acknowledge that the extent to which an MVR implant
is supra-annular can vary considerably.
Conclusions
The frequency of MVR in infants and small children has
decreased at our center in recent years, with a concomitant
increase in the use of other surgical and interventional
therapies for MV disease. Survival after MVR in children
younger than 5 years of age continues to improve. In our
more recent experience, supra-annular MVR is associated
with worse survival over time than annular MVR. In survi-
vors after supra-annular MVR, redo MVR can usually be per-
formed in the annular position with appropriate prosthesis
upsizing. Patients who undergo supra-annular MVR are
less likely to experience operative complete AV block but re-
main at risk when the supra-annular prosthesis is subse-
quently replaced with an annular prosthesis. We believe
that supra-annular MVR should be reserved for cases in
which balloon or surgical valvuloplasty has failed and in
which an annular implant is not feasible. In such circum-
stances patients typically do well in the short term but must
be followed closely for occult LA and PA hypertension.
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CH
DFigure E1. Mitral valve repair procedures during each decade
broken down by primary indication: mitral stenosis (white bars),
mitral regurgitation (hatched bars), or mixed mitral stenosis and
mitral regurgitation (black bars).961.e1 The Journal of Thoracic and Cardiovascular Surgery c October 2008
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CH
DFigure E2. Images from a retrograde left ventricular angiogram
during diastole (A) and systole (B) in a patient with an aneurysm
of the ventricularized portion of the left atrium. The ventricularized
portion of the left atrium between the prosthesis and the native
mitral valve annulus is the densely opacified area in the systolic
image. The pigtail catheter was introduced into the left ventricle
retrograde, through the aortic valve. The other catheter, a balloon-
tipped end-hole catheter, appears to be across the mitral valve
prosthesis in these images but is actually in the right ventricle.The Journal of Thoracic and Cardiovascular Surgery c Volume 136, Number 4 961.e2
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DTABLE E1. MVR prosthesis types and sizes
Prosthesis type




Dura mater 6 (5%)
St Jude–HP 5 (4%)
Allograft 1 (1%)
Prosthesis size
#17 mm 48 (41%)
18–19 mm 38 (32%)
$21 mm 32 (27%)
MVR, Mitral valve replacement.961.e3 The Journal of Thoracic and Cardiovascular Surgery c October 2008
